Efficacy and Safety of Approved First-Line TKI Treatments in mRCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Efficacy and Safety of Approved First-Line Tyrosine Kinase Inhibitor Treatments in Metastatic Renal Cell Carcinoma: A Network Meta-Analysis
Adv Ther 2019 Dec 14;[EPub Ahead of Print], KM Manz, K Fenchel, A Eilers, J Morgan, K Wittling, WCM DempkeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.